| Date Filed | Type | Description |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/31/2023 |
4
| Kantoff Philip W. (Director) has filed a Form 4 on Context Therapeutics Inc.|
Txns:
| Granted 25,000 options to buy
@ $0.87, valued at
$21.8k
|
|
| 05/31/2023 |
4
| West Linda (Director) has filed a Form 4 on Context Therapeutics Inc.|
Txns:
| Granted 25,000 options to buy
@ $0.87, valued at
$21.8k
|
|
| 05/31/2023 |
4
| Stacey Jennifer Evans (Director) has filed a Form 4 on Context Therapeutics Inc.|
Txns:
| Granted 25,000 options to buy
@ $0.87, valued at
$21.8k
|
|
| 05/31/2023 |
4
| BERMAN RICHARD J (Director) has filed a Form 4 on Context Therapeutics Inc.|
Txns:
| Granted 50,000 options to buy
@ $0.87, valued at
$43.5k
|
|
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/06/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/06/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/27/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/22/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/22/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/22/2023 |
8-K
| Quarterly results |
| 02/21/2023 |
4
| Lehr Martin A. (CEO) has filed a Form 4 on Context Therapeutics Inc.|
Txns:
| Bought 5,823 shares
@ $0.8415, valued at
$4.9k
|
|
| 02/14/2023 |
4
| Levit Alex C. (Chief Legal Officer, Corp. Sec) has filed a Form 4 on Context Therapeutics Inc.|
Txns:
| Granted 151,505 options to buy
@ $0.8407, valued at
$127.4k
|
|
| 02/14/2023 |
4
| Lehr Martin A. (CEO) has filed a Form 4 on Context Therapeutics Inc.|
Txns:
| Granted 287,544 options to buy
@ $0.8407, valued at
$241.7k
|
|
| 02/14/2023 |
4
| Minai-Azary Jennifer Lynn (CFO) has filed a Form 4 on Context Therapeutics Inc.|
Txns:
| Granted 158,001 options to buy
@ $0.8407, valued at
$132.8k
|
|
| 02/14/2023 |
SC 13G
| Context Therapeutics Inc. reports a 7.3% stake in Context Therapeutics Inc. |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/06/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/06/2023 |
8-K
| Quarterly results |
| 01/30/2023 |
4
| Lehr Martin A. (CEO) has filed a Form 4 on Context Therapeutics Inc.|
Txns:
| Bought 7,027 shares
@ $0.6974, valued at
$4.9k
|
|
| 01/27/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 01/23/2023 |
4
| Lehr Martin A. (CEO) has filed a Form 4 on Context Therapeutics Inc.|
Txns:
| Bought 6,839 shares
@ $0.7166, valued at
$4.9k
|
|
| 01/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/10/2023 |
SC 13G/A
| SABBY MANAGEMENT, LLC reports a 5% stake in Context Therapeutics Inc. |
| 01/09/2023 |
SC 13G/A
| HIRSCHMAN ORIN reports a 0% stake in Context Therapeutics Inc. |
| 01/04/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/19/2022 |
4
| Lehr Martin A. (CEO) has filed a Form 4 on Context Therapeutics Inc.|
Txns:
| Bought 20,000 shares
@ $0.7398, valued at
$14.8k
|
|
| 12/12/2022 |
4
| Levit Alex C. (Chief Legal Officer, Corp. Sec) has filed a Form 4 on Context Therapeutics Inc.|
Txns:
| Bought 6,000 shares
@ $0.8491, valued at
$5.1k
|
|
| 12/08/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 12/01/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 11/17/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
|